

Joan Domingo Gispert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5341458/publications.pdf>

Version: 2024-02-01

208
papers

6,245
citations

81839

39
h-index

95218

68
g-index

224
all docs

224
docs citations

224
times ranked

9590
citing authors

#	ARTICLE	IF	CITATIONS
1	¹⁸F sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
2	β -catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature Medicine, 2012, 18, 892-901.	15.2	336
3	The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. Journal of Neurochemistry, 2005, 92, 798-806.	2.1	241
4	Global and regional gray matter reductions in ADHD: A voxel-based morphometric study. Neuroscience Letters, 2005, 389, 88-93.	1.0	241
5	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	4.5	204
6	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in $A\beta$ pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	3.3	202
7	Biodistribution of Amino-Functionalized Diamond Nanoparticles. In Vivo Studies Based on ¹⁸ F Radionuclide Emission. ACS Nano, 2011, 5, 5552-5559.	7.3	138
8	Imaging Brain Inflammation with [¹¹ C]PK11195 by PET and Induction of the Peripheral-Type Benzodiazepine Receptor after Transient Focal Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1975-1986.	2.4	137
9	Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. NeuroImage, 2003, 19, 601-612.	2.1	125
10	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, 1358-1371.	0.4	120
11	Synthesis and In Vivo Evaluation of the Biodistribution of a ¹⁸ F-Labeled Conjugate Gold-Nanoparticle-Peptide with Potential Biomedical Application. Bioconjugate Chemistry, 2012, 23, 399-408.	1.8	100
12	Effects of APOE ϵ 4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 902-912.	0.4	98
13	The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 82-92.	1.8	97
14	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.4	86
15	Ventro-Striatal Reductions Underpin Symptoms of Hyperactivity and Impulsivity in Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2009, 66, 972-977.	0.7	83
16	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	3.0	82
17	Pediatric OCD structural brain deficits in conflict monitoring circuits: A voxel-based morphometry study. Neuroscience Letters, 2007, 421, 218-223.	1.0	80
18	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. Clinical Cancer Research, 2013, 19, 6787-6801.	3.2	80

#	ARTICLE	IF	CITATIONS
19	A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2017, 16, 343-354.	1.4	73
20	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 123.	3.0	73
21	Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECF-SEOR Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3118-3127.	0.8	73
22	InÂvivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. <i>Neurobiology of Aging</i> , 2013, 34, 1790-1798.	1.5	69
23	Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimerâ€™s dementia. <i>Environment International</i> , 2020, 138, 105546.	4.8	69
24	Method for bias field correction of brain T1-weighted magnetic resonance images minimizing segmentation error. <i>Human Brain Mapping</i> , 2004, 22, 133-144.	1.9	65
25	Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. <i>Psychopharmacology</i> , 2005, 178, 17-26.	1.5	65
26	Enhanced neural activity in frontal and cerebellar circuits after cognitive training in children with attentionâ€deficit/hyperactivity disorder. <i>Human Brain Mapping</i> , 2010, 31, 1942-1950.	1.9	64
27	N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. <i>Schizophrenia Research</i> , 2005, 73, 209-219.	1.1	58
28	In Vivo Biodistribution of Amino-Functionalized Ceria Nanoparticles in Rats Using Positron Emission Tomography. <i>Molecular Pharmaceutics</i> , 2012, 9, 3543-3550.	2.3	55
29	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
30	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. <i>Neurobiology of Aging</i> , 2016, 38, 47-55.	1.5	54
31	Cerebral metabolic patterns in chronic and recent-onset schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2003, 122, 125-135.	0.9	53
32	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 67-77.	1.2	53
33	Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 4.	3.0	53
34	Fronto-limbic dysfunction in borderline personality disorder: A 18F-FDG positron emission tomography study. <i>Journal of Affective Disorders</i> , 2011, 131, 260-267.	2.0	50
35	Gaba and serotonin molecular neuroimaging in essential tremor: A clinical correlation study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 876-880.	1.1	50
36	Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. <i>NeuroImage</i> , 2005, 27, 1002-1006.	2.1	46

#	ARTICLE	IF	CITATIONS
37	Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. <i>Neurobiology of Aging</i> , 2015, 36, 2687-2701.	1.5	46
38	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46
39	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 12.	3.0	46
40	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.4	44
41	White matter microstructure is altered in cognitively normal middle-aged APOE- ϵ 4 homozygotes. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 48.	3.0	43
42	Differences in response to food stimuli in a rat model of obesity: in-vivo assessment of brain glucose metabolism. <i>International Journal of Obesity</i> , 2008, 32, 1171-1179.	1.6	42
43	Cerebral metabolism and risperidone treatment in schizophrenia. <i>Schizophrenia Research</i> , 2003, 60, 1-7.	1.1	41
44	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. <i>Brain Imaging and Behavior</i> , 2020, 14, 2012-2023.	1.1	40
45	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. <i>Neurology</i> , 2021, 97, e2065-e2078.	1.5	40
46	Associations between air pollution and biomarkers of Alzheimer's disease in cognitively unimpaired individuals. <i>Environment International</i> , 2021, 157, 106864.	4.8	40
47	Spatial-Temporal Patterns of β 2-Amyloid Accumulation. <i>Neurology</i> , 2022, 98, .	1.5	40
48	The APOE ϵ 4 genotype modulates CSF YKL40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 50-59.	1.2	36
49	Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2003, 124, 163-175.	0.9	34
50	Hypofrontality in men with first-episode psychosis. <i>British Journal of Psychiatry</i> , 2005, 186, 203-208.	1.7	34
51	Differential abnormalities of the head and body of the caudate nucleus in attention deficit-hyperactivity disorder. <i>Psychiatry Research - Neuroimaging</i> , 2008, 163, 270-278.	0.9	34
52	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	3.3	34
53	Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. <i>Human Brain Mapping</i> , 2018, 39, 4565-4579.	1.9	32
54	Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [¹¹ C]DASB. <i>Journal of Neurochemistry</i> , 2014, 130, 126-135.	2.1	31

#	ARTICLE	IF	CITATIONS
55	Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies. <i>EJNMMI Research</i> , 2019, 9, 32.	1.1	31
56	Interactive effect of age and APOE- ϵ 4 allele load on white matter myelin content in cognitively normal middle-aged subjects. <i>NeuroImage: Clinical</i> , 2019, 24, 101983.	1.4	30
57	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 135.	3.0	30
58	P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2021, 13, e15098.	3.3	30
59	New method for routine production of L-methylmethionine: in loop synthesis. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 83-86.	0.5	29
60	Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 257-266.	2.5	29
61	Automated Method for Small-Animal PET Image Registration with Intrinsic Validation. <i>Molecular Imaging and Biology</i> , 2009, 11, 107-113.	1.3	29
62	Cerebellar neurometabolite abnormalities in pediatric attention/deficit hyperactivity disorder: A proton MR spectroscopic study. <i>Neuroscience Letters</i> , 2010, 470, 60-64.	1.0	29
63	Higher prevalence of cerebral white matter hyperintensities in homozygous APOE- ϵ 4 allele carriers aged 45-75: Results from the ALFA study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 250-261.	2.4	29
64	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101777.	1.4	29
65	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
66	Differential associations of APOE- ϵ 2 and APOE- ϵ 4 alleles with PET-measured amyloid- β and tau deposition in older individuals without dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2212-2224.	3.3	29
67	<title>Multimodality image quantification using the Talairach grid</title>. , 2001, , .		28
68	Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. <i>BMJ Open</i> , 2017, 7, e013215.	0.8	28
69	White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. <i>Human Brain Mapping</i> , 2020, 41, 1309-1322.	1.9	27
70	Dopamine D4 receptors modulate brain metabolic activity in the prefrontal cortex and cerebellum at rest and in response to methylphenidate. <i>European Journal of Neuroscience</i> , 2010, 32, 668-676.	1.2	26
71	Psychometric Properties of the Memory Binding Test: Test-Retest Reliability and Convergent Validity. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 999-1010.	1.2	26
72	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101801.	1.4	26

#	ARTICLE	IF	CITATIONS
73	Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, Dyrk1A+/? . Genes, Brain and Behavior, 2007, 6, 569-578.	1.1	25
74	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid- β and Tau. Journal of Alzheimer's Disease, 2018, 61, 1575-1587.	1.2	25
75	Central and peripheral consequences of the chronic blockade of CB ₁ cannabinoid receptor with rimonabant or taranabant. Journal of Neurochemistry, 2010, 112, 1338-13351.	2.1	24
76	Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. Journal of the American College of Cardiology, 2021, 77, 888-898.	1.2	24
77	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2169-2182.	3.3	24
78	Depressed Glucose Consumption at Reperfusion following Brain Ischemia does not Correlate with Mitochondrial Dysfunction and Development of Infarction: An in vivo Positron Emission Tomography Study. Current Neurovascular Research, 2009, 6, 82-88.	0.4	23
79	The Memory Binding Test: Development of Two Alternate Forms into Spanish and Catalan. Journal of Alzheimer's Disease, 2016, 52, 283-293.	1.2	23
80	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. Alzheimer's Research and Therapy, 2019, 11, 72.	3.0	23
81	A 18F-fluorodeoxyglucose MicroPET Imaging Study to Assess Changes in Brain Glucose Metabolism in a Rat Model of Surgery-induced Latent Pain Sensitization. Anesthesiology, 2011, 115, 1072-1083.	1.3	22
82	Association between relative temporal and prefrontal sulcal cerebrospinal fluid and illness duration in schizophrenia. Schizophrenia Research, 2002, 58, 305-312.	1.1	21
83	Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. International Clinical Psychopharmacology, 2005, 20, 13-18.	0.9	21
84	Positron emission tomography with 11C-flumazenil in the rat shows preservation of binding sites during the acute phase after 2h-transient focal ischemia. Neuroscience, 2011, 182, 208-216.	1.1	21
85	Learning non-linear patch embeddings with neural networks for label fusion. Medical Image Analysis, 2018, 44, 143-155.	7.0	21
86	Monitoring Gene Therapy by External Imaging of mRNA: Pilot Study on Murine Erythropoietin. Therapeutic Drug Monitoring, 2007, 29, 612-618.	1.0	19
87	Simultaneous Dual-tracer PET Imaging of the Rat Brain and its Application in the Study of Cerebral Ischemia. Molecular Imaging and Biology, 2011, 13, 500-510.	1.3	19
88	The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades. Journal of Alzheimer's Disease, 2018, 62, 1067-1077.	1.2	19
89	The effects of aging on dopaminergic neurotransmission: a microPET study of [11C]-raclopride binding in the aged rodent brain. Neuroscience, 2010, 171, 1283-1286.	1.1	18
90	Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer's and Family). Journal of Alzheimer's Disease, 2015, 48, 613-625.	1.2	18

#	ARTICLE	IF	CITATIONS
91	MRI-Based Screening of Preclinical Alzheimer's Disease for Prevention Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1099-1112.	1.2	18
92	APOE- ϵ 4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101818.	1.4	18
93	Impact of ventricular enlargement on the measurement of metabolic activity in spatially normalized PET. <i>NeuroImage</i> , 2007, 35, 748-758.	2.1	17
94	Environment and Brain Development: Challenges in the Global Context. <i>Neuroepidemiology</i> , 2016, 46, 79-82.	1.1	17
95	Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for SMALL-CELL LUNG Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, S35-S36.	0.4	17
96	Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. <i>NeuroImage: Clinical</i> , 2018, 19, 190-201.	1.4	16
97	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. <i>Brain</i> , 2020, 143, 976-992.	3.7	16
98	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2183-2199.	3.3	16
99	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4567-4579.	3.3	16
100	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 181-191.	1.2	15
101	Multipurpose Virtual Reality Environment for Biomedical and Health Applications. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2019, 27, 1511-1520.	2.7	15
102	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. <i>Neurobiology of Aging</i> , 2020, 95, 104-114.	1.5	15
103	Variations in the shape of the frontobasal brain region in obsessive-compulsive disorder. <i>Human Brain Mapping</i> , 2011, 32, 1100-1108.	1.9	14
104	Cerebral amyloid β 2 load is associated with neurodegeneration and gliosis: Mediation by p τ and interactions with risk factors early in the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, 788-800.	0.4	14
105	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 82.	3.0	14
106	Biodistribution and Radiation Dosimetry of the Glycine Transporter-1 Ligand 11C-GSK931145 Determined from Primate and Human Whole-Body PET. <i>Molecular Imaging and Biology</i> , 2011, 13, 776-784.	1.3	13
107	Amyloid β 2 positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. <i>Neurobiology of Aging</i> , 2021, 104, 24-31.	1.5	13
108	The protective gene dose effect of the APOE ϵ 2 allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.4	13

#	ARTICLE	IF	CITATIONS
109	Rapid and high-yielding cysteine labelling of peptides with N-succinimidyl 4-[¹⁸ F]fluorobenzoate. Chemical Communications, 2012, 48, 6118.	2.2	12
110	Simulating the effect of cerebral blood flow changes on regional quantification of [¹⁸ F]flutemetamol and [¹⁸ F]florbetaben studies. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 579-589.	2.4	12
111	Nonlinear interaction between <i>APOE</i> ϵ 4 allele load and age in the hippocampal surface of cognitively intact individuals. Human Brain Mapping, 2021, 42, 47-64.	1.9	12
112	Brain alterations in the early Alzheimer's continuum with amyloid- β , tau, glial and neurodegeneration CSF markers. Brain Communications, 2022, 4, .	1.5	12
113	<i>Statistical segmentation of multidimensional brain datasets</i> . , 2001, , .		11
114	Assessment of SPM in Perfusion Brain SPECT Studies. A Numerical Simulation Study Using Bootstrap Resampling Methods. IEEE Transactions on Biomedical Engineering, 2008, 55, 1849-1853.	2.5	11
115	In vivo molecular imaging of the GABA/benzodiazepine receptor complex in the aged rat brain. Neurobiology of Aging, 2012, 33, 1457-1465.	1.5	11
116	Changes in cerebral [¹⁸ F]-FDG uptake induced by acute alcohol administration in a rat model of alcoholism. Behavioural Brain Research, 2017, 327, 29-33.	1.2	11
117	Single-cell Transcriptional Changes in Neurodegenerative Diseases. Neuroscience, 2021, 479, 192-205.	1.1	11
118	Diazepam and Jacobson's Progressive Relaxation Show Similar Attenuating Short-Term Effects on Stress-Related Brain Glucose Consumption. European Psychiatry, 2015, 30, 187-192.	0.1	10
119	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
120	Effect of anatomical variability, reconstruction algorithms and scattered photons on the SPM output of brain PET studies. NeuroImage, 2008, 39, 1121-1128.	2.1	9
121	Comparison of positron emission tomography (PET) and computed tomography (CT) for better target volume definition in radiation therapy planning. Clinical and Translational Oncology, 2010, 12, 367-373.	1.2	9
122	Comparison of the Performance Evaluation of the MicroPET R4 Scanner According to NEMA Standards NU 4-2008 and NU 2-2001. IEEE Transactions on Nuclear Science, 2012, 59, 1879-1886.	1.2	9
123	Erythrocytes labeled with [¹⁸ F]SFB as an alternative to radioactive CO for quantification of blood volume with PET. Contrast Media and Molecular Imaging, 2013, 8, 375-381.	0.4	9
124	Novel methodology for labelling mesoporous silica nanoparticles using the ¹⁸ F isotope and their in vivo biodistribution by positron emission tomography. Journal of Nanoparticle Research, 2015, 17, 1.	0.8	9
125	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 46.	3.0	9
126	Management and Quality Control of Large Neuroimaging Datasets: Developments From the Barcelona η Brain Research Center. Frontiers in Neuroscience, 2021, 15, 633438.	1.4	9

#	ARTICLE	IF	CITATIONS
127	Comparative Analysis of Different Definitions of Amyloid- β^2 Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021, 8, 1-10.	1.5	9
128	Age, sex and APOE- β^4 modify the balance between soluble and fibrillar β^2 -amyloid in non-demented individuals: topographical patterns across two independent cohorts. <i>Molecular Psychiatry</i> , 2022, 27, 2010-2018.	4.1	9
129	Regional associations of white matter hyperintensities and early cortical amyloid pathology. <i>Brain Communications</i> , 2022, 4, .	1.5	9
130	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. <i>NeuroImage: Clinical</i> , 2022, 35, 103106.	1.4	9
131	[11C]-DASB microPET imaging in the aged rat: Frontal and meso-thalamic increases in serotonin transporter binding. <i>Experimental Gerontology</i> , 2011, 46, 1020-1025.	1.2	8
132	Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging. <i>NeuroImage</i> , 2021, 232, 117821.	2.1	8
133	Genetic Influences on Hippocampal Subfields. <i>Neurology: Genetics</i> , 2021, 7, e591.	0.9	8
134	Cognitively unimpaired individuals with a low burden of $A\beta^2$ pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 134.	3.0	8
135	Positron Emission Tomographic Imaging of the Cannabinoid Type 1 Receptor System with [11C]OMAR ([11C]JHU75528): Improvements in Image Quantification Using Wild-Type and Knockout Mice. <i>Molecular Imaging</i> , 2011, 10, 7290.2011.00019.	0.7	7
136	Evaluation of Hypoxic Tissue Dynamics with ^{18}F -FMISO PET in a Rat Model of Permanent Cerebral Ischemia. <i>Molecular Imaging and Biology</i> , 2011, 13, 558-564.	1.3	7
137	APOE- β^4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. <i>Cerebral Cortex</i> , 2020, 30, 4110-4120.	1.6	7
138	Brain correlates of urban environmental exposures in cognitively unimpaired individuals at increased risk for Alzheimer's disease: A study on Barcelona's population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12205.	1.2	7
139	Genetic Predisposition to Alzheimer's Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region. <i>Genes</i> , 2021, 12, 825.	1.0	7
140	Parametric imaging of dual-time window [18F]flutemetamol and [18F]florbetaben studies. <i>NeuroImage</i> , 2021, 234, 117953.	2.1	7
141	Assessing Lung Inflammation After Nanoparticle Inhalation Using 2-deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Imaging. <i>Molecular Imaging and Biology</i> , 2014, 16, 264-273.	1.3	6
142	Modeling practice effects in healthy middle-aged participants of the Alzheimer and Families parent cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 149-158.	1.2	6
143	Projection to Latent Spaces Disentangles Pathological Effects on Brain Morphology in the Asymptomatic Phase of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 648.	1.1	6
144	Quantitative informant and self-reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE β^4 . <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12127.	1.2	6

#	ARTICLE	IF	CITATIONS
145	Impact of cerebral blood flow and amyloid load on SUVR bias. <i>EJNMMI Research</i> , 2022, 12, 29.	1.1	6
146	Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia. <i>Neurotoxicity Research</i> , 2002, 4, 437-451.	1.3	5
147	ROC evaluation of statistical wavelet-based analysis of brain activation in [15O]-H ₂ O PET scans. <i>NeuroImage</i> , 2005, 24, 763-770.	2.1	5
148	Comparison of NEMA NU 4-2008 vs NEMA NU 2-2001 for the performance evaluation of the microPET R4 system. , 2009, , .		5
149	Efficient cysteine labelling of peptides with N-succinimidyl 4-[18F]fluorobenzoate: stability study and in vivo biodistribution in rats by positron emission tomography (PET). <i>RSC Advances</i> , 2013, 3, 8028.	1.7	5
150	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE- β 4 in middle-age cognitively unimpaired individuals from the ALFA study. <i>Brain Structure and Function</i> , 2020, 225, 2331-2345.	1.2	5
151	Genotypic effects of <i>APOE</i> - β 4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. <i>Cerebral Cortex</i> , 2023, 33, 2748-2760.	1.6	5
152	P2 β 505: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITY CORRELATES WITH COGNITION IN THE ALFA COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P925.	0.4	4
153	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1413-1422.	1.2	4
154	Inhomogeneity correction of magnetic resonance images by minimization of intensity overlapping. , 0, , .		3
155	Characterization of the Biodistribution and Systemic Absorption of TT-173, a New Hemostatic Agent of Recombinant Human Tissue Factor, Using Radiolabeling with 18F. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 583-592.	0.6	3
156	The Crus exhibits stronger functional connectivity with executive network nodes than with the default mode network. <i>Brain</i> , 2018, 141, e24-e24.	3.7	3
157	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. <i>Neurology</i> , 2020, 95, e2065-e2074.	1.5	3
158	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 119-128.	1.2	3
159	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	3
160	Harmonization of amyloid PET scans minimizes the impact of reconstruction parameters on centiloid values. <i>Alzheimer's and Dementia</i> , 2020, 16, e045294.	0.4	2
161	Quantitative amyloid PET in the AMYPAD diagnostic and patient management study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
162	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2

#	ARTICLE	IF	CITATIONS
163	Optimization of [¹¹ C]Raclopride Positron Emission Tomographic Rat Studies: Comparison of Methods for Image Quantification. <i>Molecular Imaging</i> , 2013, 12, 7290.2012.00040.	0.7	1
164	[P1â€“395]: AMYPAD: A EUROPEAN PUBLICâ€“PRIVATE PARTNERSHIP TO INVESTIGATE THE VALUE OF Î²â€“AMYLOID BRAIN SCANS AS A DIAGNOSTIC AND THERAPEUTIC MARKER FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P420.	0.4	1
165	Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease: A Predictive Study. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 365-376.	3.9	1
166	Emerging betaâ€“amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. <i>Alzheimer's and Dementia</i> , 2020, 16, e044466.	0.4	1
167	Impact of APOE â€“4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. <i>Alzheimer's and Dementia</i> , 2020, 16, e045828.	0.4	1
168	Higher levels of the astrocytic marker CSF YKL40 are associated with better memory performance only in amyloidâ€“positive individuals with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
169	Cognitive function and neuroimaging correlates in a subjective cognitive decline population within a multimodal intervention supplemented with green tea extract (PENSA Study): Preliminary results of a voxelâ€“based morphometry study. <i>Alzheimer's and Dementia</i> , 2021, 17, e055894.	0.4	1
170	Subjective cognitive decline is associated with higher anxiety and depression during the COVIDâ€“19â€“related confinement. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
171	An evaluation of simultaneous dual-tracer technique for PET static studies. , 2009, , .		0
172	Partial volume correction using an energy multiresolution analysis. , 2009, , .		0
173	Subjective cognitive decline correlates with medial temporal lobe and hippocampal subfield volumetry in cognitively unimpaired participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e043520.	0.4	0
174	Amyloidâ€“2, tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimerâ€“s continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044444.	0.4	0
175	Genetically predicted telomere length and Alzheimerâ€“s disease endophenotypes: A Mendelian randomization study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044720.	0.4	0
176	The effect of physical activity on CSF biomarkers of Alzheimerâ€“s disease differs between men and women. <i>Alzheimer's and Dementia</i> , 2020, 16, e044722.	0.4	0
177	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044733.	0.4	0
178	Higher frontoâ€“parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. <i>Alzheimer's and Dementia</i> , 2020, 16, e044780.	0.4	0
179	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, e044808.	0.4	0
180	PENSA study: Study design, recruitment profiles and participant inclusion in multimodal intervention studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e045074.	0.4	0

#	ARTICLE	IF	CITATIONS
181	APOE $\epsilon 4$ shapes temporo-parietal network properties in middle-aged, cognitively unimpaired individuals: A graph theory analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, e045092.	0.4	0
182	Weight loss predicts Alzheimer's disease biomarker positivity in cognitively unimpaired middle-aged adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045137.	0.4	0
183	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. <i>Alzheimer's and Dementia</i> , 2020, 16, e045171.	0.4	0
184	Incidence of subjective cognitive decline is associated with amyloid β pathology, whereas stability relates to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2020, 16, e045293.	0.4	0
185	Amyloid-positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. <i>Alzheimer's and Dementia</i> , 2020, 16, e045715.	0.4	0
186	The Barcelona dementia prevention research clinic: Study design, recruitment profiles and inclusion in prevention studies – An update. <i>Alzheimer's and Dementia</i> , 2020, 16, e045800.	0.4	0
187	ALFA+: A cohort study to understand and model the preclinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045935.	0.4	0
188	NeAT: a Nonlinear Analysis Toolbox for Neuroimaging. <i>Neuroinformatics</i> , 2020, 18, 517-530.	1.5	0
189	Soundtrack of life: An fMRI study. <i>Behavioural Brain Research</i> , 2022, 418, 113634.	1.2	0
190	Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies. <i>Methods in Molecular Biology</i> , 2018, 1750, 165-184.	0.4	0
191	Association between telomere length and cognitive function among cognitively unimpaired individuals at risk of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
192	Midlife subclinical atherosclerosis and cardiovascular risk factors linked to hypometabolism in Alzheimer's disease relevant regions. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
193	Brain structural alterations in cognitively unimpaired individuals with discordant amyloid β PET and CSF A β 42 status: Findings using machine learning. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
194	Sex differences in genetic susceptibility of hippocampal subfields: A polygenic association study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
195	Prediction of amyloid pathology in cognitively unimpaired individuals using structural MRI. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
196	Machine learning on combined neuroimaging and plasma biomarkers for triaging participants of secondary prevention trials in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
197	Imaging neurodegeneration markers are associated with multiple pathophysiological mechanisms in the early stages of the Alzheimer's continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
198	Optimal parametric imaging methods for dual-time-window [¹⁸ F]flutemetamol and [¹⁸ F]florbetaben PET studies. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
199	Synergistic effects of CSF A β 42 and p τ on functional resting-state connectivity in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
200	Cross-sectional associations between sleep quality reports and core Alzheimer's disease biomarkers in cognitively unimpaired adults from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
201	Data-driven approach for early detection of pathological pathways in middle-aged adults with family history of sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
202	Structural, metabolic and cognitive characteristics of cognitively unimpaired subjects with mismatching β -amyloid biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
203	Associations between iron deposition in the brain and grey matter volumes in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
204	Neuroimaging-derived phenotypes in the European Prevention of Alzheimer Dementia (EPAD) Cohort Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
205	Association of body mass index with brain structure and biomarkers of inflammation in cognitively unimpaired middle-aged adults with and without evidence of β -amyloid pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
206	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
207	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
208	Sex, caregiver status and amyloid positivity predict increased anxiety and depression during the COVID-19-related confinement. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0